Furthermore, it is not easy to predict which metastatic melanoma patients will be able to respond to with immunotherapy because of the lack of deep understanding of the cellular and molecular mechanisms that lead to PD-1 blockade resistance. This evidence concerns the gene PDCD1 and metastatic melanoma.